Altered contractility in mutation-specific hypertrophic cardiomyopathy: A mechano-energetic in silico study with pharmacological insights

Altered contractility in mutation-specific hypertrophic cardiomyopathy: A mechano-energetic in silico study with pharmacological insights

Introduction: Mavacamten (MAVA), Blebbistatin (BLEB), and Omecamtiv mecarbil (OM) are promising drugs directly targeting sarcomere dynamics, with demonstrated efficacy against hypertrophic cardiomyopathy (HCM) in (pre)clinical trials. However, the molecular mechanism affecting cardiac contractility...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Mohamadamin Forouzandehmehr, Michelangelo Paci, Jussi T Koivumäki, Jari Hyttinen
Formaat: Artikel
Taal:English
Gepubliceerd in: Frontiers Media S.A. 2022-10-01
Reeks:Frontiers in Physiology
Onderwerpen:
in silico modeling
human stem cell-derived cardiomyocyte
action potential
immature cardiomyocytes
cardiac metabolism
hypertrophic cardiomyopathy
Online toegang:https://www.frontiersin.org/articles/10.3389/fphys.2022.1010786/full

Internet

https://www.frontiersin.org/articles/10.3389/fphys.2022.1010786/full

Gelijkaardige items